Stemline Therap Drug Patent Portfolio
Stemline Therap owns 1 orange book drug protected by 8 US patents Given below is the list of Stemline Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10385008 | Polymorphic forms of RAD1901-2HCL | 05 Jan, 2038 | Active |
| US10745343 | Polymorphic forms of RAD1901-2HCl | 05 Jan, 2038 | Active |
| US11819480 | Methods for treating cancer | 29 Nov, 2036 | Active |
| US10071066 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
| US10420734 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
| US11779552 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
| US7612114 | Selective estrogen receptor modulator | 18 Aug, 2026 | Active |
| US8399520 | Selective estrogen receptor modulator | 25 Dec, 2024 | Active |
Latest Legal Activities on Stemline Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Stemline Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 09 Apr, 2024 | US11819480 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 08 Apr, 2024 | US11819480 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 08 Apr, 2024 | US11819480 |
| Adjustment of PTA Calculation by PTO | 05 Apr, 2024 | US11819480 |
| Pet Dec Routed to Certificate of Corrections Branch | 05 Apr, 2024 | US11819480 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 05 Apr, 2024 | US11819480 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10071066 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US8399520 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10420734 |
| Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US7612114 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Jan, 2024 | US10745343 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US7612114 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US8399520 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US10071066 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US10420734 |
Stemline Therap's Family Patents
Stemline Therap drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 41.5% of its total global patent coverage. Click
below to unlock the full patent family tree.
Stemline Therap Drug List
Given below is the complete list of Stemline Therap's drugs and the patents protecting them.
1. Orserdu
Orserdu is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10385008 | Polymorphic forms of RAD1901-2HCL |
05 Jan, 2038
(13 years from now)
| Active |
| US10745343 | Polymorphic forms of RAD1901-2HCl |
05 Jan, 2038
(13 years from now)
| Active |
| US11819480 | Methods for treating cancer |
29 Nov, 2036
(12 years from now)
| Active |
| US10071066 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(10 years from now)
| Active |
| US10420734 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(10 years from now)
| Active |
| US11779552 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(10 years from now)
| Active |
| US7612114 | Selective estrogen receptor modulator |
18 Aug, 2026
(1 year, 10 months from now)
| Active |
| US8399520 | Selective estrogen receptor modulator |
25 Dec, 2024
(2 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orserdu's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List